Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PPBT with free AI briefings, catalyst countdowns, and dilution alerts.

PPBT · PURPLE BIOTECH LTD.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.1M Cash on Hand
9.4mo Cash Runway
Follow PPBT by email Get an email when PPBT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PPBT, unsubscribe in one click. Privacy

📣 What PPBT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
IRS1/IRS2/STAT3 Inhibitor NT219 Head and Neck Cancer Phase 1/2 · NCT06919666 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PPBT holds $6.1M in cash and short-term investments and burns about $1.9M/quarter from operations, an estimated runway of 9.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PPBT files for a raise →

👥 Who Owns PPBT

Insiders 2.2% Institutions 16.2% Public and other holders 81.6%
HolderTypeShares% of sharesAs of
Mitchell P. Kopin Institution (13G, 5%+) 206,941,858 11.13% 2026-09-30
Susquehanna Securities, LLC Institution (13G, 5%+) 93,953,400 5.05% 2025-12-31
Gil Efron
Chief Executive Officer
Insider 15,750,000 0.85% 2026-03-18
Michael Schickler
Head of Clinical & Reg Affairs
Insider 9,254,472 0.50% 2026-03-18
Shai S Lankry
Chief Financial Officer
Insider 3,550,000 0.19% 2026-03-18
Simcha Rock
Director
Insider 3,207,690 0.17% 2026-03-18
Ido Agmon
Director
Insider 3,093,860 0.17% 2026-03-18
Suzana Zilberberg
Director
Insider 3,062,500 0.16% 2026-03-18
Robert E. Gagnon
Director
Insider 3,062,500 0.16% 2026-03-18
Ayrton Capital LLC Institution (13G, 5%+) 103,250 0.01% 2026-09-30

Share count 1,858,911,801 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PPBT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PPBT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.